MET and acute myeloid leukemia: Merestinib potently blocks AXL and MET phosphorylation, and the subsequent activation of their downstream signaling molecules, and has demonstrated anti-leukemic effects by effective blockade of eukaryotic translation initiation factor 4E (eIF4E) phosphorylation in AML cells [144].